NasdaqHealth CarePharmaceutical PreparationsHELLERUP, Denmark

Ascendis Pharma A/S ASND

Ask your AI

Estimated market cap $17.07B61.98M shares, shares as of Dec 31, 2025CIK 1612042

Insider trades, 12 mo

9 buys · 3 sells

$5.51M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

226

97 added · 59 trimmed

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in Ascendis Pharma A/S's latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

12 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Sep 8, 2026. Insiders have two business days to file.

Recent insider trades

Mads Bodenhoff SVP & PAO	Sep 8 Form 4 ↗	Sale	−$810.6K 3,000 sh @ $270.19	+3.5%
Lars Holtug Director	Sep 2 Form 4 ↗	Sale	−$62.3K 236 sh @ $264.13	+4.4%
Jean Jacques Bienaime Director	Aug 14 Form 4 ↗	Buy	+$222.2K 900 sh @ $246.91	+13.7%
Jean Jacques Bienaime Director	Aug 14 Form 4 ↗	Buy	+$270.4K 1,100 sh @ $245.85	+13.7%
Scott Thomas Smith EVP & Chief Financial Officer	Jun 2 Form 4 ↗	Buy	+$21.9K 100 sh @ $219.00	+27.8%

All ASND insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

28.88M shares

226 funds report ASND. Values checked against market prices.

Funds report more than 100% of shares (Q2 2026)

302 funds hold the stock.

Q3 2026: 47% · 5,560 of ~8,900 funds reported so far

Q1 202613%
Q2 2026>100%
Q3 2026 (so far)47%

Q3 2026. 52 new, 97 added to, 59 trimmed, 130 exited since Q2 2026.

Top 13F holders
#
1	Westfield Capital Management Co LP 13F ↗	5.13M	$1.2B	+6.8%
2	FMR LLC 13F ↗	3.45M	$785.0M	-2.8%
3	BlackRock, Inc. 13F ↗	2.28M	$520.4M	+3.3%
4	Artisan Partners Limited Partnership 13F ↗	2.08M	$474.6M	-20.9%
5	Massachusetts Financial Services Co 13F ↗	1.90M	$431.9M	+1.1%
6	Capital International Investors 13F ↗	1.42M	$322.9M	-28.7%
7	Franklin Templeton Inc 13F ↗	1.11M	$285.9M	-40.5%
8	American Century Companies Inc 13F ↗	1.25M	$285.1M	-10.7%
9	Principal Financial Group Inc 13F ↗	1.17M	$265.5M	+33.4%
10	Capital World Investors 13F ↗	908,029	$206.9M	+0.2%

Download CSV Every fund that holds ASND, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Ascendis Pharma A/S and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Ascendis Pharma A/S and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2026	8	—	7.94M	$1.8B
Q2 2026	303	+295	65.85M	$17.6B
Q3 2026	226	-77	28.88M	$6.6B

Each point is a quarter-end, from Q1 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (K08588103). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes9 in 12 mo 8-K eventsNone in 90 days Patents11 patents granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 28 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials8 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Ascendis Pharma A/S
Address: TUBORG BOULEVARD 12, HELLERUP, Denmark
Phone: 45 70 22 22 44
Fiscal year ends: Dec 31
Filer category: Large accelerated filer
Incorporated in: Denmark
Listed as: ASND (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$275.39+$8.32 (+3.12%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $223.21 · High $275.39Nov 13, 2026

Aug 13, 2026Low $222.69 · High $275.39Nov 13, 2026

Nov 13, 2025Low $196.63 · High $277.18Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.